FBLG: Phase 1/2 Trial of CYWC628 Underway

FBLG Business Update Phase 1/2 Trial of CYWC628 Underway On June 3, 2026, FibroBiologics, Inc. (NASDAQ: FBLG) announced that ...

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.
News Medical

Using cell painting for image-based phenotypic profiling in 3D spheroid model of breast cancer

Most potential oncology drugs fail during the drug development pipeline, even when there has been promising data for their efficacy during the in vitro stage. This makes it vital to identify in vitro ...
BioTechniques

Application Note: Real-time live-cell analysis of multi-spheroid, co-cultured, 3D tumor assays

In this Application Note, Sartorius describes the use of the Incucyte® Live-Cell Analysis System and Incucyte® 3D Multi-Tumor Spheroid Assays to study the growth of 3D tumor multi-spheroids in ...